{'fraction_non_alphanumeric': 0.025, 'fraction_numerical': 0.015625, 'mean_word_length': 5.248780487804878, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 1, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Significance of an immunoenzyme assay of the prostate-specific acid phosphatase (PAP) (E.C.3.1.3.2.) in prostatic carcinoma. Methods and initial clinical results].

The usefulness of a new specific immunoenzymatic assay for the prostatic acid phosphatase for diagnosis and monitoring of prostatic carcinoma has been investigated. The results include 200 healthy men without urologic anamnesis, 50 patients suffering from prostatic adenoma, and 152 patients with prostatic carcinoma. Out of 152 patients with prostatic carcinoma 110 were so-called therapy-responders and 42 were patients with progression of prostatic cancer. The immunoenzymatic assay for PAP shows good results for the separation of patients with progressive prostatic carcinoma, from those patients with a stationary prostatic cancer as well as for monitoring of prostatic carcinoma. The diagnostic value of the test has been found significantly higher than that of previous tests with different substrates. As this method allows the direct measurement of the activity of the specific prostatic acid phosphatase in U/l there is no need to run a standard-curve. It is recommended to use different "normal ranges" for patients with and without therapy. For monitoring mainly intraindividual studies are requested.